Reviva Pharmaceuticals (RVPH) - 2024 Q3 - Quarterly Report

Fair Value of Warrant Liabilities - Fair value of warrant liabilities as of September 30, 2024: $77,884, compared to$806,655 as of December 31, 2023[97] - Change in fair value of warrant liabilities for the nine months ended September 30, 2024: $(728,771), compared to$305,972 for the same period in 2023[97] Lattice Model Parameters - Risk-free interest rate used in Lattice model: 3.91% as of September 30, 2024, compared to 4.25% as of December 31, 2023[98] - Remaining expected term of Private Warrants: 1.21 years as of September 30, 2024, compared to 1.96 years as of December 31, 2023[98] - Expected volatility used in Lattice model: 123.60% as of September 30, 2024, compared to 89.00% as of December 31, 2023[98] - Stock price on valuation date: $1.44 as of September 30, 2024, compared to$5.15 as of December 31, 2023[98] - Exercise price of Private Warrants: $11.50 as of September 30, 2024 and December 31, 2023[98] Stock Options and Vesting - Grant of 730,000 nonqualified stock options to non-executive employees on October 30, 2024, with an exercise price of$1.16[99] - Vesting periods for granted stock options range from sixteen months to thirty-eight months[99] Market Risk Disclosures - The company is not required to provide quantitative and qualitative disclosures about market risk as a smaller reporting company[175]